Have questions? Visit https://www.reddit.com/r/SNPedia


From SNPedia

Geno Mag Summary
(G;G) 3 lower odds of responding to PEG-IFNalpha/RBV treatment
(G;T) 2 Moderately lower odds of responding to PEG-IFNalpha/RBV treatment
(T;T) 0 common
ReferenceGRCh38 38.1/141
is asnp
is mentioned by
1000 genomesrs8099917
23andMe allrs8099917
SNP Nexus

GWAS Ctlgrs8099917
Max Magnitude3
? (G;G) (G;T) (T;T) 28
23andMe blog

rs8099917(C) less likely to respond to Hepatitis C treatment.

rs12979860(C;C) better able to become naturally Hepatitis C virus-free. rs12980275(A) usually corresponds to the rs12979860(C)

GWAS snp
PMID [PMID 19749758]
Trait Response to Hepatitis C treatment
Title IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy
Risk Allele G
P-val 9E-9
Odds Ratio 1.98 [1.57-2.52]
GWAS snp
PMID [PMID 19749757]
Trait Response to Hepatitis C treatment
Title Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C
Risk Allele G
P-val 3E-32
Odds Ratio 27.10 [14.6-50.3]
GWAS snp
PMID [PMID 20060832]
Trait Chronic Hepatitis C infection
Title Genetic variation in IL28B Is Associated with Chronic Hepatitis C and Treatment Failure - A Genome-Wide Association Study
Risk Allele G
P-val 6E-9
Odds Ratio 2.31 [1.74-3.06]

[PMID 20576307] A common variation of IL28 affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients

[PMID 20803561OA-icon.png] Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection

[PMID 21068134] HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy


[PMID 21382156] Genes and hepatitis C: susceptibility, fibrosis progression and response to treatment

[PMID 21384511] Relationship between the interleukin-28b gene polymorphism and the histological severity of hepatitis C virus-induced graft inflammation and the response to antiviral therapy after liver transplantation

GWAS snp
PMID [PMID 21228123]
Title IL-28B predicts response to chronic hepatitis C therapy -fine-mapping and replication study in Asian populations
Risk Allele G
P-val 1E-20
Odds Ratio 3.0000 [2.4-3.8]

[PMID 21618576] Impact of viral amino acid substitutions and host IL28B polymorphism on replication and susceptibility to interferon of hepatitis C virus

[PMID 21722179] Predicting response to therapy in chronic hepatitis C: an approach combining IL28B gene polymorphisms and clinical data

[PMID 21390311OA-icon.png] Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms

[PMID 21914076] IL28B polymorphism may guide pegylated interferon plus ribavirin therapy even after curative treatment for hepatitis C virus-related hepatocellular carcinoma

[PMID 21987611OA-icon.png] IL28B polymorphisms associated with therapy response in Chilean chronic hepatitis C patients

[PMID 21994136OA-icon.png] Ultra-Rapid Virological Response, Young Age, Low ?-GT/ALT-Ratio, and Absence of Steatosis Identify a Subgroup of HCV Genotype 3 Patients Who Achieve SVR with IFN-?(2a) Monotherapy

[PMID 22032680] Eradication of hepatitis C virus genotype 1 after liver transplantation by interferon therapy before surgery: Report of three patients with analysis of interleukin-28 polymorphism, hepatitis C virus core region and interferon-sensitivity determining region

[PMID 22052088] Interleukin-28B genotypes determine response to pegylated-interferon plus ribavirin therapy in patients with hepatitis C virus infection

[PMID 22087138OA-icon.png] Single nucleotide polymorphisms of the IL28B and sustained virologic response of patients with chronic hepatitis C to PEG-interferon/ribavirin therapy: A meta-analysis: Meta-analysis of IL28B

[PMID 22118055] Single and combined IL28B, ITPA and SLC28A3 host genetic markers modulating response to anti-hepatitis C therapy

[PMID 22174846OA-icon.png] Hepatic STAT1-Nuclear Translocation and Interleukin 28B Polymorphisms Predict Treatment Outcomes in Hepatitis C Virus Genotype 1-Infected Patients

[PMID 22234924] Combined effects of different IL28B gene variants on the outcome of dual combination therapy in chronic HCV type 1 infection

[PMID 22257210] A Tetra-Primer Amplification Refractory Mutation System-Polymerase Chain Reaction for the Detection of rs8099917 IL28B Genotype

[PMID 22336553] [Studies on the relationship between polymorphism of IL-28B rs8099917 and the outcome of HBV infection]

[PMID 22336134OA-icon.png] Paradoxical expression of IL-28B mRNA in peripheral blood in human T-cell leukemia virus Type-1 mono-infection and Co-infection with hepatitis C Virus

[PMID 22356575] The outcomes of glucose abnormalities in pre-diabetic chronic hepatitis C patients receiving peginterferon plus ribavirin therapy

[PMID 22374338] Evaluation of interleukin 28B single nucleotide polymorphisms in infants suffering from bronchiolitis

[PMID 21745312] Association of interleukin 28B and mutations in the core and NS5A region of hepatitis C virus with response to peg-interferon and ribavirin therapy

[PMID 22521237] Closed tube method for rapid screening of IL28B polymorphisms involved in response to hepatitis C treatment

[PMID 22550527OA-icon.png] Development and Validation of a Simple, Rapid and Inexpensive PCR-RFLP Method for Genotyping of Common IL28B Polymorphisms: A Useful Pharmacogenetic Tool for Prediction of Hepatitis C Treatment Response

[PMID 22156487] Association of interleukin-28B and hepatitis C genotype 1 with a high viral load and response to pegylated interferon plus ribavirin therapy

[PMID 22193282] Host interleukin-28B genetic variants versus viral kinetics in determining responses to standard-of-care for Asians with hepatitis C genotype 1.

[PMID 22649509OA-icon.png] IL28B Genetic Variation Is Associated with Spontaneous Clearance of Hepatitis C Virus, Treatment Response, Serum IL-28B Levels in Chinese Population

[PMID 22591106] Meta-analysis: IL28B polymorphisms predict sustained viral response in HCV patients treated with pegylated interferon-α and ribavirin.

[PMID 22387386] Predicting sustained viral response to hepatitis C using a rapid and simple IL28B rs8099917 genotyping assay.

[PMID 22713131OA-icon.png] Prediction of response to pegylated-interferon-¿ and ribavirin therapy in Chinese patients infected with different hepatitis C virus genotype

[PMID 20434452] Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C.

[PMID 20648473] Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin.

[PMID 20708617] Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C.

[PMID 20728570] Impact of IL28B genotype on the early and sustained virologic response in treatment-naive patients with chronic hepatitis C.

[PMID 21048934OA-icon.png] IL28B SNP rs8099917 is strongly associated with pegylated interferon-alpha and ribavirin therapy treatment failure in HCV/HIV-1 coinfected patients.

[PMID 21080244] The IL-28 genotype: how it will affect the care of patients with hepatitis C virus infection.

[PMID 21112657] Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients.

[PMID 21112660] Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2b.

[PMID 21145800] IL28 variation affects expression of interferon stimulated genes and peg-interferon and ribavirin therapy.

[PMID 21145807] Early virologic response and IL28B polymorphisms in patients with chronic hepatitis C genotype 3 treated with peginterferon alfa-2a and ribavirin.

[PMID 21254157] Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients.

[PMID 21274371OA-icon.png] Peginterferon and ribavirin treatment for hepatitis C virus infection.

[PMID 21321200OA-icon.png] Association of IL28B gene variations with mathematical modeling of viral kinetics in chronic hepatitis C patients with IFN plus ribavirin therapy.

[PMID 21325786] Amino Acid Substitution in HCV Core Region and Genetic Variation near the IL28B Gene Affect Viral Dynamics during Telaprevir, Peginterferon and Ribavirin Treatment.

[PMID 21354446] IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C.

[PMID 21360545] Association of IL28B variants with response to pegylated-interferon alpha plus ribavirin combination therapy reveals intersubgenotypic differences between genotypes 2a and 2b.

[PMID 21374656] IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection.

[PMID 21389156OA-icon.png] The rs8099917 polymorphism, when determined by a suitable genotyping method, is a better predictor for response to pegylated alpha interferon/ribavirin therapy in Japanese patients than other single nucleotide polymorphisms associated with interleukin-28B.

[PMID 21466653] Donor and recipient IL28B polymorphisms in HCV-infected patients undergoing antiviral therapy before and after liver transplantation.

[PMID 21501223] Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in Asian patients.

[PMID 21503910] Prediction of response to peginterferon-alfa-2b plus ribavirin therapy in Japanese patients infected with hepatitis C virus genotype 1b.

[PMID 21567424] Impact of genetic polymorphisms near the IL28B gene and amino acid substitutions in the hepatitis C virus core region on interferon sensitivity/resistance in patients with chronic hepatitis C.

[PMID 21613433OA-icon.png] Interleukin-28B genotyping by melt-mismatch amplification mutation assay PCR analysis using single nucleotide polymorphisms rs12979860 and rs8099917, a useful tool for prediction of therapy response in hepatitis C patients.

[PMID 21692944] IL28B polymorphisms determine early viral kinetics and treatment outcome in patients receiving peginterferon/ribavirin for chronic hepatitis C genotype 1.

[PMID 21703176] Interleukin-28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24 weeks peginterferon/ribavirin.

[PMID 21704279OA-icon.png] Simultaneous genotyping of rs12979860 and rs8099917 variants near the IL28B locus associated with HCV clearance and treatment response.

[PMID 21721028] Genetic variation in the interleukin-28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection.

[PMID 21739446] Antiviral combination therapy with peginterferon and ribavirin does not induce a therapeutically resistant mutation in the HCV core region regardless of genetic polymorphism near the IL28B gene.

[PMID 21879313] Genotype rs8099917 near the IL28B gene and amino acid substitution at position 70 in the core region of the hepatitis C virus are determinants of serum apolipoprotein B-100 concentration in chronic hepatitis C.

[PMID 21889215] IL28B polymorphisms are not associated with the response to interferon-beta in multiple sclerosis.

[PMID 21898478] Association of gene expression involving innate immunity and genetic variation in interleukin 28B with antiviral response.

[PMID 21900787] A single IL28B genotype SNP rs12979860 determination predicts treatment response in patients with chronic hepatitis C Genotype 1 virus.

[PMID 21907615] Polymorphism near the IL28B gene in Korean hepatitis C virus-infected patients treated with peg-interferon plus ribavirin.

[PMID 21911885] Genetic variation in interleukin-28B predicts SVR in hepatitis C genotype 1 Argentine patients treated with PEG IFN and ribavirin.

[PMID 22013224OA-icon.png] IL28B rs12979860 genotype and spontaneous clearance of hepatitis C virus in a multi-ethnic cohort of injection drug users: evidence for a supra-additive association.

[PMID 22095536] Predictive value of early viral dynamics during peginterferon and ribavirin combination therapy based on genetic polymorphisms near the IL28B gene in patients infected with HCV genotype 1b.

[PMID 22098416] IL28B polymorphisms are markers of therapy response and are influenced by genetic ancestry in chronic hepatitis C patients from an admixed population.

[PMID 22098610] Clinical impact of HFE mutations in Japanese patients with chronic hepatitis C.

[PMID 22180014] IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes.

[PMID 22180419OA-icon.png] IL28B polymorphisms influence stage of fibrosis and spontaneous or interferon-induced viral clearance in thalassemia patients with hepatitis C virus infection.

[PMID 22192885] Serum level of IP-10 increases predictive value of IL28B polymorphisms for spontaneous clearance of acute HCV infection.

[PMID 22209781] Evaluation of susceptibility locus for response to interferon-alpha based therapy in chronic hepatitis B patients in Chinese.

[PMID 22239510] Serum PAI-1 is a novel predictor for response to pegylated interferon-alpha-2b plus ribavirin therapy in chronic hepatitis C virus infection.

[PMID 22245236] Association of IL28B gene polymorphism with development of hepatocellular carcinoma in Japanese patients with chronic hepatitis C virus infection.

[PMID 22310928] Genetic variation in IL28B is associated with the development of hepatitis B-related hepatocellular carcinoma.

[PMID 22314430] IL28B and PNPLA3 polymorphisms affect histological liver damage in patients with non-alcoholic fatty liver disease.

[PMID 22325058] Association of polymorphisms in interleukin-18 and interleukin-28B with Hepatitis B recurrence after liver transplantation in Chinese Han population.

[PMID 22329371] IL28B genetic variants and gender are associated with spontaneous clearance of hepatitis C virus infection.

[PMID 22350701] IL28B polymorphism is associated with fatty change in the liver of chronic hepatitis C patients.

[PMID 22382633] Randomized trial of peginterferon alpha-2a plus ribavirin versus peginterferon alpha-2b plus ribavirin for chronic hepatitis C in Japanese patients.

[PMID 22404723] Lymphotropic hepatitis C virus has an interferon-resistant phenotype.

[PMID 22432893] IL28B SNP of donors and recipients can predict virological response to PEGIFN/RBV therapy in patients with recurrent hepatitis C after living donor liver transplantation.

[PMID 22438096] Association of two polymorphisms of the IL28B gene with viral factors and treatment response in 1,518 patients infected with hepatitis C virus.

[PMID 22441534] Prediction of response to pegylated interferon/ribavirin combination therapy for chronic hepatitis C genotype 1b and high viral load.

[PMID 22505587] Vitamin D levels and IL28B polymorphisms are related to rapid virological response to standard of care in genotype 1 chronic hepatitis C.

[PMID 22537149] Development of new IL28B genotyping method using Invader Plus assay.

[PMID 22613000] Insulin resistance undermines the advantages of IL28B polymorphism in the pegylated interferon alpha-2b and ribavirin treatment of chronic hepatitis C patients with genotype 1.

[PMID 22664181] A straightforward genotyping of the relevant IL28B SNPs for the prediction of hepatitis C treatment outcome.

[PMID 22966241OA-icon.png] The impact of interferon lambda 3 gene polymorphism on natural course and treatment of hepatitis C

GET Evidence
impact pathogenic
qualified_impact Insufficiently evaluated pathogenic
overall_frequency 0.15625

[PMID 23118765OA-icon.png] Hepatitis C virus clearance after discontinuation of pegylated interferon alpha-2a monotherapy in a child

[PMID 23133602OA-icon.png] Pharmacogenetics of Efficacy and Safety of HCV Treatment in HCV-HIV Coinfected Patients: Significant Associations with IL28B and SOCS3 Gene Variants

[PMID 23149444] Negative Predictive Value of IL28B, SLC28A2, and CYP27B1 SNPs and Low RBV Plasma Exposure for Therapeutic Response to PEG/IFN-RBV Treatment

[PMID 23189850] [Genetic variation of IL-28B is associated with treatment response of patients with chronic hepatitis C]

[PMID 23252241] [Immunogenetic predictors of a rapid virologic response to antiviral therapy in patients with chronic hepatitis C]

[PMID 23442843] Role of Interleukin 28B-related Gene Polymorphisms in Chronic Hepatitis C and the Response to Antiviral Therapy in Koreans

[PMID 23490371] Genetic variations in host IL28B links to the detection of peripheral blood mononuclear cells-associated hepatitis C virus RNA in chronically infected patients

[PMID 23029188OA-icon.png] Test of IL28B polymorphisms in chronic hepatitis C patients treated with PegIFN and ribavirin depends on HCV genotypes: results from a meta-analysis

[PMID 23109451] IL28B polymorphisms predict the response to chronic hepatitis C virus infection treatment in a Mexican population

[PMID 23020144] Polymorphisms in interleukin-10 and interleukin-28B genes in Egyptian patients with chronic hepatitis C virus genotype 4 and their effect on the response to pegylated interferon/ribavirin-therapy

[PMID 23782163] Interleukin-28B genetic variations and spontaneous clearance of hepatitis C antibody-positive blood donors in China

[PMID 23860735] Genetic variation near interleukin 28B and the risk of hepatocellular carcinoma in patients with chronic hepatitis C

[PMID 23866096] The predictive value of IL28B rs12979860, rs11881222 and rs8099917 polymorphisms and IP-10 in the therapeutic response of Egyptian genotype 4 patients

[PMID 23231085] IL28B polymorphisms predict response to therapy among chronic hepatitis C patients with HCV genotype 4

[PMID 23426277] Association of interleukin-28B genotype and hepatocellular carcinoma recurrence in patients with chronic hepatitis C

[PMID 24130799OA-icon.png] microRNA-122 Abundance in Hepatocellular Carcinoma and Non-Tumor Liver Tissue from Japanese Patients with Persistent HCV versus HBV Infection

[PMID 24192751] Telaprevir is effective given every 12 hours at 750 mg with peginterferon-alfa-2b and ribavirin to Japanese patients with HCV-1b IL28B rs8099917 TT

[PMID 24197875OA-icon.png] Utility of Telaprevir-Resistant Variant Detection for Prediction of Treatment Efficacy in HCV Genotype 1

[PMID 23197895OA-icon.png] Novel biosensor-based microarray assay for detecting rs8099917 and rs12979860 genotypes

[PMID 24303092OA-icon.png] IL-28B polymorphisms and treatment response in hepatitis C virus patients with persistently normal alanine aminotransferase

[PMID 24355007] Genetic polymorphism in IFNL4 and response to pegylated interferon-α and ribavirin in Japanese chronic hepatitis C patients

[PMID 24477330] A case of successful hepatitis C virus eradication by 24 weeks of telaprevir-based triple therapy for a hemophilia patient with hepatitis C virus/human immunodeficiency virus co-infection who previously failed pegylated interferon-α and ribavirin therapy

[PMID 24553484] Impact of Comorbid Hepatic Steatosis on Treatment of Chronic Hepatitis C in Japanese Patients and the Relationship with Genetic Polymorphism of IL28B, PNPLA3 and LDL Receptor

[PMID 24620020] Immunomodulatory function of interleukin-28B during primary infection with Cytomegalovirus

[PMID 24621321OA-icon.png] Severe thrombocytopenia in a patient with inosine triphosphatase (ITPA)-CC genotype caused by pegylated interferon (IFN)-alpha-2a with ribavirin therapy: a case report

[PMID 22536875] Factors responsible for the discrepancy between IL28B polymorphism prediction and the viral response to peginterferon plus ribavirin therapy in Japanese chronic hepatitis C patients.

[PMID 22612669] Efficacy of reduction therapy of natural human beta-interferon and ribavirin in elderly patients with chronic hepatitis C, genotype 1b and high viral load.

[PMID 22626609] Factors that predict response of patients with hepatitis C virus infection to boceprevir.

[PMID 22742526] Meta-analysis: the impact of IL28B polymorphisms on rapid and sustained virological response in HCV-2 and -3 patients.

[PMID 22806754] Complicated relationships of amino acid substitution in hepatitis C virus core region and IL28B genotype influencing hepatocarcinogenesis.

[PMID 22814458OA-icon.png] Targeting both rs12979860 and rs8099917 polymorphisms with a single-tube high-resolution melting assay for IL28b genotyping.

[PMID 22842190] Interleukin-28B polymorphisms on the SVR in the treatment of naive chronic hepatitis C with pegylated interferon-alpha plus ribavirin: a meta-analysis.

[PMID 22850127] The genotype frequencies of IL28B polymorphisms (rs12979860, rs8099917) among Turkish patients with hepatitis C.

[PMID 22863264] Genetic polymorphism in cyclooxygenase-2 promoter affects hepatic inflammation and fibrosis in patients with chronic hepatitis C.

[PMID 22863269] Interleukin-28B (IL-28B) single-nucleotide polymorphisms and interferon plus ribavirin treatment outcome in Italian chronically HCV-infected patients.

[PMID 22889955] Raloxifene hydrochloride is an adjuvant antiviral treatment of postmenopausal women with chronic hepatitis C: a randomized trial.

[PMID 22898703] Interleukin 28B genetic polymorphisms play a minor role in identifying optimal treatment duration in HCV genotype 1 slow responders to pegylated interferon plus ribavirin.

[PMID 22913807] Genetic polymorphism of IL28B in hepatitis C-infected haemophilia patients in Israel.

[PMID 22930507] Association of IL28B genotype and viral response of hepatitis C virus genotype 2 to interferon plus ribavirin combination therapy.

[PMID 23103287] IL28B polymorphisms are associated with severity of liver disease in human immunodeficiency virus (HIV) patients coinfected with hepatitis C virus.

[PMID 23135173] Analysis of IL28B alleles with virologic response patterns and plasma cytokine levels in HIV/HCV-coinfected patients.

[PMID 23142377] Association study of IL28B: rs12979860 and rs8099917 polymorphisms with SVR in patients infected with chronic HCV genotype 1 to PEG-INF/RBV therapy using systematic meta-analysis.

[PMID 23145987] Early extensive viremia, but not rs8099917 genotype, is the only predictor for cholestatic hepatitis C after living-donor liver transplantation.

[PMID 23154876] Baseline factors and early viral response (week 4) to antiviral therapy with peginterferon and ribavirin for predicting sustained virologic response in patients infected with hepatitis C virus genotype 1: a multicenter study.

[PMID 23161429] Add-on therapy of pitavastatin and eicosapentaenoic acid improves outcome of peginterferon plus ribavirin treatment for chronic hepatitis C.

[PMID 23213063] Human blood dendritic cell antigen 3 (BDCA3)(+) dendritic cells are a potent producer of interferon-lambda in response to hepatitis C virus.

[PMID 23216931] Serum peptides, represented by complement 3f des-arginine, are useful for prediction of the response to pegylated interferon-alpha plus ribavirin in patients with chronic hepatitis C.

[PMID 23246359] Profound week 4 interferon responsiveness is mandatory for hepatitis C genotype 1 patients with unfavorable IL-28B genotype.

[PMID 23266640] Interleukin-28B rs12979860C/T and rs8099917T/G contribute to spontaneous clearance of hepatitis C virus in Caucasians.

[PMID 23296193] IL-21R gene polymorphisms and serum IL-21 levels predict virological response to interferon-based therapy in Asian chronic hepatitis C patients.

[PMID 23297176] Model incorporating the ITPA genotype identifies patients at high risk of anemia and treatment failure with pegylated-interferon plus ribavirin therapy for chronic hepatitis C.

[PMID 23314745OA-icon.png] Impact of IL-28B polymorphisms on pegylated interferon plus ribavirin treatment response in children and adolescents infected with HCV genotypes 1 and 4.

[PMID 23333445OA-icon.png] Differential effects of donor and recipient IL28B and DDX58 SNPs on severity of HCV after liver transplantation.

[PMID 23356752] Pegylated interferon monotherapy in patients with chronic hepatitis C with low viremia and its relationship to mutations in the NS5A region and the single nucleotide polymorphism of interleukin-28B.

[PMID 23449268] HLA-DP and IL28B polymorphisms: influence of host genome on hepatitis B surface antigen seroclearance in chronic hepatitis B.

[PMID 23455512OA-icon.png] IL28B SNP screening and distribution in the French Canadian population using a rapid PCR-based test.

[PMID 23486666] 'Favourable' IL28B polymorphisms are associated with a marked increase in baseline viral load in hepatitis C virus subtype 3a infection and do not predict a sustained virological response after 24 weeks of therapy.

[PMID 23490377] Value of IL28B genotyping in patients with HCV-related mixed cryoglobulinemia: results of a large, prospective study.

[PMID 23490380] An automated rapid detection system using the quenching probe method for detecting interleukin 28B and inosine triphosphatase single nucleotide polymorphisms in chronic hepatitis C.

[PMID 23560893] Clinical utility of host genetic IL-28B variants in hepatitis C virus genotype 1 Asian patients retreated with pegylated interferon plus ribavirin.

[PMID 23565619] IL28RA polymorphism is associated with early hepatitis C virus (HCV) treatment failure in human immunodeficiency virus-/HCV-coinfected patients.

[PMID 23586360] Association between gene polymorphisms of IL-28 and response to lamivudine in Chinese rural patients with chronic hepatitis B.

[PMID 23591768OA-icon.png] Ex vivo induction of IFN-lambda3 by a TLR7 agonist determines response to Peg-IFN/ribavirin therapy in chronic hepatitis C patients.

[PMID 23611115] Impact of interleukin 28B polymorphisms on spontaneous clearance of hepatitis C virus infection: a meta-analysis.

[PMID 23611467] CARD8 gene encoding a protein of innate immunity is expressed in human atherosclerosis and associated with markers of inflammation.

[PMID 23613588OA-icon.png] Serum microRNA-122 level correlates with virologic responses to pegylated interferon therapy in chronic hepatitis C.

[PMID 23689988] Using early viral kinetics to predict antiviral outcome in response-guided pegylated interferon plus ribavirin therapy among patients with hepatitis C virus genotype 1.

[PMID 23689989] IL28B minor allele is associated with a younger age of onset of hepatocellular carcinoma in patients with chronic hepatitis C virus infection.

[PMID 23730840] Role of IL28B and inosine triphosphatase polymorphisms in the treatment of chronic hepatitis C virus genotype 6 infection.

[PMID 23777929] Searching for an immunogenetic factor that will illuminate susceptibility to non-tuberculous mycobacterial disease.

[PMID 23829453] Value of interleukin-28B genetic polymorphism on retreatment outcomes of chronic hepatitis C genotype 1 relapsers by peginterferon alfa plus ribavirin.

[PMID 24750345] ITPA genetic variants influence efficacy of PEG-IFN/RBV therapy in older patients infected with HCV genotype 1 and favourable IL28B type

[PMID 24379268] [The role of hepcidin and polymorphisms in the regulatory region of the IL-28B gene in HCV infections]

[PMID 24914551OA-icon.png] Impact of Host IL28B rs12979860, rs8099917 in Interferon Responsiveness and Advanced Liver Disease in Chronic Genotype 3 Hepatitis C Patients

[PMID 24929144] KIR3DL1-HLA-Bw4 Combination and IL28B Polymorphism Predict Response to Peg-IFN and Ribavirin with and without Telaprevir in Chronic Hepatitis C

[PMID 24379617OA-icon.png] Interleukin 28B polymorphisms as predictor of response in hepatitis C virus genotype 2 and 3 infected patients

[PMID 25032184OA-icon.png] No association between the IL28B SNP and response to peginterferon plus ribavirin combination treatment in Korean chronic hepatitis C patients

[PMID 24204859OA-icon.png] Association of IFNL3 rs12979860 and rs8099917 with biochemical predictors of interferon responsiveness in chronic hepatitis C virus infection

[PMID 24117654] Impact of IL28B polymorphisms on 24-week telaprevir-based combination therapy for Asian chronic hepatitis C patients with hepatitis C virus genotype 1b

[PMID 25233462OA-icon.png] IL28B Gene Polymorphism SNP rs8099917 Genotype GG Is Associated with HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP) in HTLV-1 Carriers

[PMID 24349054OA-icon.png] No correlation between PNPLA3 rs738409 genotype and fatty liver and hepatic cirrhosis in Japanese patients with HCV

[PMID 25563035OA-icon.png] Demographics, clinical characteristics, IFNL3- and IFNL4- polymorphisms in a cohort of hepatitis C patients from Puerto Rico

[PMID 25652367] IL28B rs12980275 polymorphism shows association with response to treatment in Pakistani patients with Chronic Hepatitis C

[PMID 25664396] Gene polymorphisms of interleukin 28B and the risk to chronic hepatitis B virus infection in Thai

[PMID 25769643] IL28B rs12980275 variant as a predictor of sustained virologic response to pegylated-interferon and ribavirin in chronic hepatitis C patients: A systematic review and meta-analysis

[PMID 25803108OA-icon.png] Favourable IFNL3 Genotypes Are Associated with Spontaneous Clearance and Are Differentially Distributed in Aboriginals in Canadian HIV-Hepatitis C Co-Infected Individuals

[PMID 25810555OA-icon.png] Deep Sequencing and Phylogenetic Analysis of Variants Resistant to Interferon-Based Protease Inhibitor Therapy in Chronic Hepatitis Induced by Genotype-1b Hepatitis C Virus

[PMID 25852275OA-icon.png] Interferon-λ3 polymorphisms in pegylated-interferon-α plus ribavirin therapy for genotype-2 chronic hepatitis C


[PMID 25904097] The clinical features of patients with a Y93H variant of hepatitis C virus detected by a PCR invader assay

[PMID 25907669] Associations between responses to interferon therapy and genetic variation in interleukin-28B and the core region of hepatitis C virus genotype 3a

[PMID 26003758] Assessment of interleukin 28B genotype as a predictor of response to combined therapy with pegylated interferon plus ribavirin in HCV infected Egyptian patients

[PMID 24118788] Genetic variation in interleukin 28B and correlation with chronic hepatitis B virus infection in Saudi Arabian patients

[PMID 24924923] The relationship between IL-28B polymorphisms and the response to peginterferon alfa-2a monotherapy in anti-HBe-positive patients with chronic HBV infection

[PMID 25376093OA-icon.png] Association between single-nucleotide polymorphisms and early spontaneous hepatitis B virus e antigen seroconversion in children

[PMID 25503988OA-icon.png] IL-28B is a key regulator of B- and T-cell vaccine responses against influenza

[PMID 26263394OA-icon.png] Prevalence of HIV, Hepatitis B and C Infections and an Assessment of HCV-Genotypes and Two IL28B SNPs among People Who Inject Drugs in Three Regions of Nepal

[PMID 25938745] IL28B polymorphisms of both recipient and donor cooperate to influence IFN treatment response in HCV recurrence after liver transplantation, but IL28B SNPs of the recipient play a major role in IFN-induced blocking of HCV replication

[PMID 26281194] [Impact of interleukin-10 and interleukin-28 gene polymorphisms on the development and course of lupus nephritis]

[PMID 26400298] Association of polymorphism within the interleukin-28 receptor alpha gene, but not in interleukin-28B, with lower urinary tract symptoms (LUTS) in Chinese

[PMID 25661337] Role of pharmacogenetic in ribavirin outcome prediction and pharmacokinetics in an Italian cohort of HCV-1 and 4 patients

[PMID 26060059] Role of IL28B genotyping in patients with hepatitis C virus-associated mixed cryoglobulinemia and response to PEG-IFN and ribavirin treatment

[PMID 24840315] Interleukin-28 gene polymorphisms may contribute to HBsAg persistence and the development of HBeAg-negative chronic hepatitis B

[PMID 25312023] IL28B genetic variations are associated with treatment response of patients with chronic hepatitis C in a Chinese Han population

Risk rs8099917(G;G)
Alt rs8099917(G;G)
Reference rs8099917(T;T)
Significance Drug-response
Disease interferons peginterferon alfa-2a
Variation info
CLNDBN interferons, peginterferon alfa-2a, peginterferon alfa-2b, and ribavirin response - Efficacy peginterferon alfa-2a, peginterferon alfa-2b, ribavirin, and telaprevir response - Efficacy
Reversed 0
HGVS NC_000019.9:g.39743165T>G
CLNSRC PharmGKB Clinical Annotation PharmGKB
CLNACC RCV000211192.1, RCV000211316.1,